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ABSTRACT
Lenalidomide is a potent anti-myeloma drug with immunomodulatory properties. 
It is increasingly used in a low-dose maintenance setting to prolong remission duration 
after standard treatment. Data on the in vivo effects of lenalidomide are scarce and 
sometimes different from the well-described in vitro effects. We therefore evaluated 
the numerical, phenotypical and functional impact of lenalidomide maintenance on 
several immune cell types in a cohort of seventeen homogeneously treated myeloma 
patients achieving a low residual myeloma burden after a bortezomib based-induction 
followed by autologous stem cell transplantation. Lenalidomide maintenance: 1) 
increased the fraction of naïve CD8+ T cells and several memory T-cell subsets, 
2) reduced the numbers of terminal effector CD8+ T cells, 3) resulted in a higher 
expression of co-stimulatory molecules on resting T cells and of the inhibitory 
checkpoint molecules LAG-3 on CD4+ T cells and TIM-3 on CD4+ and CD8+ T cells, 4) 
reduced the number of TIGIT+ CD8+ T cells, 5) increased the number of regulatory 
T cells with a phenotype associated with strong suppressive capacity. Purified CD8+ 
T cells showed increased and more polyfunctional recall viral responses. However, 
PBMC responses were not enhanced during lenalidomide maintenance and CD4+ T-cell 
responses specific for the myeloma-associated antigen MAGE-C1 even tended to 
become lower. We conclude that lenalidomide maintenance after autologous stem cell 
transplantation has complex pleotropic effects on the immune environment. Immune 
interventions such as anti-myeloma vaccination should include measures to tackle an 
expanded inhibitory Treg compartment. 
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INTRODUCTION
Maintenance treatment with the immunomodulatory 
drug (IMiD) lenalidomide prolongs progression-free and 
overall survival in multiple myeloma (MM) patients 
after autologous stem cell transplantation (ASCT). An 
important mechanism of action of lenalidomide is its 
effect on the immune system, which is heavily disrupted 
in MM patients. Various studies have demonstrated the 
in vitro immunomodulatory effects of lenalidomide: 
increased natural killer (NK) cell cytotoxicity [1], 
improved functionality of invariant NKT cells [2] and 
T-cell co-stimulatory capacity [1, 3], resulting in broad 
and polyfunctional antigen-specific T-cell responses with 
a high antigen sensitivity [4, 5]. Interestingly, the addition 
of lenalidomide to T-cell cultures results in a decreased 
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expression of the inhibitory immune checkpoint molecule 
programmed death protein 1 (PD-1) while potentiating 
responses to a dendritic cell (DC)/myeloma fusion 
vaccine [6]. Lenalidomide diminishes the expression of 
suppressor of cytokine signaling (SOCS)1 on T cells, 
NK cells and NKT cells from both the bone marrow and 
the peripheral blood of MM patients [7]. Furthermore, 
lenalidomide induces the degradation of T cell repressors 
through modulation of cereblon [8]. Finally, lenalidomide 
inhibits the proliferation and T-cell suppressive function of 
regulatory T cells (Tregs) in vitro [5, 6, 9]. 
The in vivo effects of lenalidomide treatment on 
the immune environment are much less documented. 
A recent study demonstrated that CD4+ T cells play a 
major role in the therapeutic effects of lenalidomide on 
immunocompetent mice bearing 5TGM1 MM cells. In 
addition, lenalidomide significantly increased the numbers 
of IFN-γ+ T cells and perforin+ CD8+ T cells while slightly 
reducing the numbers of Tregs in this mouse model [10]. 
Busch et al. compared immune characteristics of MM 
patients treated with a lenalidomide mono- or combination 
therapy to these of MM patients treated with other agents. 
They found that a lenalidomide-containing treatment 
regimen was associated with higher numbers of CD8+ T 
cells phenotypically staged between memory T cells and 
effector memory T cells. In addition, lenalidomide-treated 
patients showed a higher abundance of CD14+ CD15+ 
myeloid cells with a T-cell inhibitory capacity (MDSCs) 
[11]. Clave et al. studied the effect of lenalidomide 
treatment on T-cell immune reconstitution in patients with 
MM who had undergone ASCT. Lenalidomide impaired 
long-term thymic T-cell reconstitution, decreased the 
number of CD4+ and CD8+ CD45RA+ CCR7- terminal 
effector T cells while increasing the number of Tregs [12]. 
Lenalidomide induction or maintenance therapy does 
not affect NKT cell numbers [13]. Recently, Krämer et 
al. compared the immune environment in MM patients 
treated with or without lenalidomide. They found 
increased frequencies of CD8+ T-cell responses for the 
MM-associated antigen HM1.24 in patients treated with 
lenalidomide compared to patients without lenalidomide 
treatment [14]. Upon PMA/ionomycin stimulation higher 
numbers of IFN-γ, TNF-α and IL-21 secreting T cells were 
detected in MM patients under lenalidomide maintenance 
treatment compared to MM patients that did not receive 
lenalidomide [15]. 
Since in vitro and in vivo studies report conflicting 
results on certain aspects of immunomodulation mediated 
through lenalidomide and given the rather limited 
information currently available on the in vivo effects of 
lenalidomide given as mono-therapy in maintenance 
treatment, we performed a detailed analysis to further 
elucidate the effects of this immunomodulating drug on 
the immune environment in MM patients achieving a low 
tumor burden after ASCT.
RESULTS
Patient predisposition and timepoints
The patient characteristics are summarized in 
Table 1. Median age at diagnosis was 59.2 years. 
5/17 patients had ISS stage 3 and 2/17 had adverse 
cytogenetics at diagnosis (either a gain of 1q, deletion 17p 
or translocation (4;14)), leading to 7 high risk patients. 
All patients received a bortezomib based induction 
(either bortezomib-dexamethasone (VD) or bortezomib-
thalidomide-dexamethasone (vtD)). 4/17 patients received 
2 additional cycles of vtD consolidation after ASCT. 10/17 
obtained a VGRP, 1/17 a CR and 6/17 obtained a stringent 
CR after ASCT or consolidation. The pre-LEN timepoint 
was assessed at a median of 18.1 weeks, LEN was started 
at a median of 25.6 weeks and the LEN timepoint was 
assessed at a median of 41.3 weeks, all after ASCT. The 
median duration of LEN maintenance was 18.0 weeks 
(range : 8–37.4 weeks).
Lenalidomide maintenance therapy results 
in higher numbers of naïve CD8+ T cells and 
memory T cells while reducing the number of 
terminal effector T cells
We evaluated the effects of lenalidomide maintenance 
treatment on the distribution of CD4+ and CD8+ T cells over 
several subtypes (Figure 1A and Supplementary Figure 
1). Our flow cytometry staining panel was based on a 
publication by Mahnke et al. [16]. We observed that the 
percentage of naïve CD8+ T cells increased significantly 
during lenalidomide maintenance (mean: 0.36% versus 
1.15%) while the frequency of naïve CD4+ T cells remained 
stable (mean: 2.99% versus 3.03%). The fraction of stem 
cell memory CD8+ T cells showed an increase (mean: 
0.22% pre-LEN versus 0.37% LEN) yet stem cell memory 
CD4+ T cells remained stable during the treatment (1.96% 
pre-LEN versus 1.25% LEN, respectively). The percentages 
of central memory CD4+ and CD8+ T cells were both 
significantly higher during the lenalidomide maintenance 
therapy (mean: 3.81% versus 6.06% and 0.16% versus 
0.61%, respectively). In addition, we observed a highly 
significant increased number of transitional memory T 
cells upon lenalidomide treatment (mean: 50.34% versus 
57.88% for the CD4+ T cells and 13.09% versus 25.31% 
for the CD8+ T cells). Lenalidomide maintenance resulted 
in lower percentages of effector memory CD4+ T cells 
(mean: 6.39% versus 4.15%), but this difference was not 
statistically significant. In contrast, within the CD8+ T-cell 
population, the fraction of effector memory T cells did 
increase significantly during lenalidomide maintenance 
treatment (from 13.77% to 20.23%, on average). Finally, 
the percentage of terminal effector T cells decreased in both 
CD4+ and CD8+ T-cell compartments upon lenalidomide 
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maintenance and this difference was significant in the CD8+ 
T-cell compartment (mean: from 2.82% to 1.33% and from 
33.20% to 22.47%, respectively). 
We further investigated the capacity of the T cells 
to produce cytokines upon activation by performing 
a multiplex assay. As shown in Figure 1B, the capacity 
of the CD4+ T cells to produce IL-8 was significantly 
increased during lenalidomide maintenance (mean: 3992 
pg/ml versus 7532 pg/ml). The CD8+ T cells obtained 
during lenalidomide maintenance produced higher 
amounts of IFN-γ (mean: 4550 pg/ml versus 12496 pg/
ml) MIP-1β (mean: 5567 pg/ml versus 9583 pg/ml) and 
TNF-α (mean: 6156 pg/ml versus 10128 pg/ml). For the 
other tested cytokines, no significant differences between 
the pre-LEN and the LEN timepoint were detected.
Interestingly, lenalidomide treatment also resulted 
in a higher CD4+/CD8+ T cell ratio (mean: 1.66 before and 
2.30 during lenalidomide maintenance) (Figure 1C). No 
significant differences in the frequency of NK cell numbers 
were observed between both timepoints. We did find higher 
percentages of NKT cells during lenalidomide maintenance 
treatment (3.05% NKT cells pre-LEN versus 4.22% NKT 
cells during LEN) (Figure 1D and Supplementary Figure 2).
Lenalidomide maintenance therapy has opposite 
effects on Treg and monocytic MDSC numbers
Next to the immune effector cells, we evaluated 
the frequency of some immune suppressive cell types 
in the patients. We assessed the percentage of Tregs 
(gating strategy, see Supplementary Figure 3) before 
and during lenalidomide (Figure 2A). We observed a 
highly significant increase in the number of Tregs upon 
lenalidomide maintenance (mean: 3.14% versus 7.91%). 
Compared to MM patients, healthy donors showed lower 
Treg numbers (mean: 2.22%) and the difference with MM 
patients treated with lenalidomide was highly significant 
(Supplementary Figure 4). We further evaluated the 
presence of MDSCs in our patients. Since granulocytic 
cells are not present in the PBMCs we had available for the 
analysis, we focused on monocytic MDSCs (moMDSCs, 
gating strategy see Supplementary Figure 3). In contrast to 
the Tregs, we observed significantly reduced percentages 
of moMDSCs defined as percentage of CD33+ CD11b+ 
CD14+ HLA-DRlow cells within the PBMC population 
(Figure 2B) (15.04% versus 11.31%) during lenalidomide 
treatment. Also the percentage of CD33+ CD11b+ cells 
within the PBMC population showed a significant drop 
(29.86% versus 21.73%) during lenalidomide therapy.
Given the significant impact of lenalidomide 
maintenance on Treg numbers, we investigated further 
whether lenalidomide maintenance also affected the Treg 
phenotype. We measured the expression of CD45RA, CD28, 
T-cell immunoglobulin and mucin-domain containing-3 
(TIM-3), T-cell immunoglobulin and immunoreceptor 
tyrosine-based inhibitory motif (TIGIT), lymphocyte 
activation gene 3 (LAG-3), CD27 and inducible T cell co-
stimulator (ICOS) on Tregs by flow cytometry (Figure 2C). 
Table 1: Patient characteristics
Patient


















 1 63,2 2 F NO VD × 4 NO sCR 25,9 28,0 62,0
 2 59,2 1 F NO vtD × 4 NO VGPR 22,4 25,6 54,6
 3 63,0 1 F NO vtD × 4 NO VGPR 35,4 38,1 48,6
 4 51,7 2 F YES (gain 1q) VD × 4 NO VGPR 16,4 17,6 29,6
 5 60,0 2 F NO VD × 4 NO sCR 18,9 24,0 41,0
 6 63,6 2 M YES (t(4;14) and del(17p)) vtD × 4 NO VGPR 15,9 29,0 47,0
 7 62,7 1 M NA vtD × 4 NO sCR 15,9 20,7 41,0
 8 64,7 3 M NA vtD × 4 vtD × 2 VGPR 23,9 26,9 57,3
 9 66,0 3 M NO vtD × 4 vtD×2 CR 25,9 29,6 59,0
10 61,9 3 F NA vtD × 4 NO VGPR 13,1 17,1 39,9
11 52,0 3 M NO vtD × 4 vtD x 2 VGPR 12,9 25,0 46,0
12 58,1 2 M NO vtD × 4 vtD x 2 VGPR 23,1 26,0 41,3
13 53,7 3 F NA vtD × 4 NO CR 14,1 16,3 24,3
14 59,1 1 F NO VD × 5 NO VGPR 15,4 27,1 64,6
15 58,4 2 M NO vtD × 4 NO sCR 21,9 29,7 40,0
16 55,9 2 F NO vtD × 4 NO sCR 18,1 21,3 35,3
17 51,9 1 M NO vtD × 4 NO VGPR 17,1 25,0 39,3
VD: Bortezomib - Dexamethasone. vtD: Bortezomib-Thalidomide-Dexamethasone. VGPR: Very good partial response. CR: complete response. sCR: stringent complete 
response. NA: not available. ISS: international staging system. M: Male, F: Female. 
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Figure 1: Lenalidomide maintenance treatment results in increased numbers of naïve CD8+ T cells and memory T 
cells while reducing the number of terminal effector T cells. PBMCs obtained before (pre LEN) and during (LEN) lenalidomide 
maintenance treatment were examined by flow cytometry to determine the number of different types of immune effector cells (n = 17). (A) 
The proportion of CD4+ and CD8+ T cells belonging several T cell subsets was determined. Naïve T cells were defined as CD45RO– CCR7+ 
CD28+ CD95–, stem cell memory T cells were defined as CD45RO– CCR7+ CD28+ CD95+, central memory T cells were defined as CD45RO+ 
CCR7+ CD28+ CD95+, transitional memory T cells were defined as CD45RO+ CCR7– CD28+ CD95+, effector memory T cells were defined 
as CD45RO+ CCR7– CD28– CD95+ and terminal effector T cells were defined as CD45RO– CCR7– CD28– CD95+ (Cfr. Supplementary 
Figure 1). (B) Cytokine production upon polyclonal stimulation was analyzed using multiplex assay. Cytokine measured upon culture in the 
absence of stimulus was considered as background and subtracted from cytokine concentrations measured upon stimulation with anti-CD3 
and anti-CD28 coated microbeads. Results were analyzed using two-way ANOVA with Sidak’s multiple comparison tests. (C) The ratio 
of CD4+/CD8+ T cells is depicted on the graph. (D) The percentage of NK cells was defined as the percentage of CD3– CD56+ CD16+ cells 
within the PBMC population. The percentage of NKT cells was defined as the percentage of CD3+ CD56+ cells. The Wilcoxon matched-
pairs signed rank test was performed to evaluate statistical significant differences, ns: not significant, *p ≤ 0.05, **p ≤ 0.01 and ****p ≤ 0.0001.
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Figure 2: Lenalidomide maintenance therapy has opposite effects on Treg and monocytic MDSC numbers. PBMCs 
obtained before (pre LEN) and during (LEN) lenalidomide maintenance treatment were examined by flow cytometry to determine the 
number of different types of immune suppressive cells. (A) The proportion of Tregs, defined as CD4+ CD25high CD127low Foxp3high cells 
(Cf. Supplementary Figure 3), was determined (n = 17). (B) The percentage of monocytic MDSC (moMDSC), defined as the percentage 
of CD14+ HLA-DRlow cells within either the PBMCs or the CD11b+ population as well as the percentage of CD11b+ CD33+ PBMCs was 
determined (n = 7). (C) The phenotype of Tregs was further dissected. The expression of CD45RA, CD28, TIM-3, TIGIT, LAG-3, CD27, 
GITR, HLA-DR, CCR7, CD62L and ICOS on Tregs was evaluated (n = 10). The Wilcoxon matched-pairs signed rank test was performed 
to evaluate statistical significant differences, ns: not significant, *p ≤ 0.05, **p ≤ 0.01, ***p < 0.001 and ****p < 0.0001.
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Of these markers, a significant increase in the percentage 
of CCR7+ (mean: 12.12 versus 18.29), CD62L+ (mean: 
14,10 versus 28,69) and HLA-DR+ (mean: 25.75 versus 
44.42) Tregs was observed upon lenalidomide treatment 
concomitant with a reduced percentate of CD45RA+ Tregs 
(40.37% versus 28.27%)
Effects of lenalidomide maintenance therapy 
on T-cell expression of co-stimulatory and co-
inhibitory molecules
The important role of stimulatory and inhibitory 
immune checkpoint molecules on the T-cell surface in 
tumor immunology is becoming more and more obvious. 
We investigated the expression of the co-stimulatory 
molecules CD28, CD137/4-1BB, OX40 and ICOS on the 
surface of CD4+ and CD8+ T cells. OX40 was the only 
of the co-stimulatory receptor of which the expression 
was not significantly up-regulated on the T cells during 
lenalidomide treatment (Figure 3, panels A and C). CD28 
expression was observed on average on 31.30% and 
41.41% of the CD8+ T cells before and during lenalidomide, 
respectively. For the CD4+ T cells the mean percentage 
of CD28+ cells raised from 85.15% to 90.65% during 
treatment. The mean percentage of CD137+ T cells raised 
from 0.89% to 1.85% and from 1.04% to 2.68% for the 
CD8+ and the CD4+ T-cell population, respectively. Finally, 
on average 16.59% CD8+ T cells expressed ICOS before 
lenalidomide treatment and this percentage increased to 
31.19% during treatment. For the CD4+ T cells, on average 
36.76% and 47.37% of the cells expressed ICOS before and 
during lenalidomide treatment, respectively.
For the co-inhibitory molecules, we observed a low 
(always <10% and typically <2%) expression of PD-1, 
TIM-3 and LAG-3 on T cells from MM patients, while 
the expression of TIGIT on both CD4+ and CD8+ T-cell 
compartments was much more pronounced (Figure 3, 
panels B and C). On the CD8+ T cells, the expression of 
TIM-3 was significantly increased upon lenalidomide 
maintenance therapy (mean: 0.26% versus 1.14%) while 
the percentage of TIGIT+ cells showed a significant drop 
(46.75% versus 23.97%). No significant effects were 
observed concerning PD-1 or LAG-3 expression on 
CD8+ T cells. On the CD4+ T cells, TIM-3 and LAG-3 
expression were higher during lenalidomide treatment 
(0.36% versus 1.64% and 0.28 versus 0.55, respectively) 
whereas lenalidomide had no significant effects on 
expression of PD-1 or TIGIT.
Lenalidomide maintenance therapy results in 
an improved CD8+ T cell functionality, which 
is hampered by non-CD8+ T cells present in the 
periphery
A pool of peptides containing HLA-class I restricted 
epitopes from CMV, EBV and influenza (CEF) was 
used to stimulate PBMCs obtained before and during 
lenalidomide maintenance treatment. These peptides elicit 
recall responses in the majority of individuals expressing 
these common MHC class I alleles since the majority has 
been previously exposed to these pathogens. We measured 
the T-cell IFN-γ production with an ex vivo ELISPOT 
assay (Figure 4A). In 5 out of 6 patients, we could detect 
CEF-specific T cells before and during lenalidomide 
treatment. We did not observe an effect of the lenalidomide 
treatment on the number of spot forming units (SFU) 
(Figure 4A, left part). However, in 5 out of 6 patients, we 
visually observed larger and more intense spots. This was 
evidenced by a modest increase of the activity, which is a 
measure for the amount of cytokine that is released by the 
T cells (Figure 4A, right part). However the increased of 
the activity did only reach statistical significance in one 
patient (p = 0.0625). 
To further elaborate on CD8+ T-cell functionality, we 
performed a three-parameter FLUOROSPOT assay, this 
time using purified CD8+ T cells stimulated with the same 
CEF peptide pool. Performing this assay, we observed 
a significant increased number of IFN-γ, TNF-α and 
IL-2 spots (Figure 4B). In addition, the degree of CD8+ 
T-cell polyfunctionality was significantly increased upon 
lenalidomide maintenance treatment (Figure 4, panels 
C-E). On average, the number of mono-functional spots 
(only IFN-γ, TNF-α or IL-2) increased 1.9 times upon 
lenalidomide maintenance treatment while the number of 
bi-functional spots (IFN-γ+TNF-α, IFN-γ+IL-2 or TNF-
α+IL-2) increased 4.3 times and the number of three-
functional spots (IFN-γ+TNF-α+IL-2) increased >17.6 
times.
Lenalidomide maintenance therapy does not 
enhance MM-specific CD4+ T-cell responses
Using cellular material from the pre LEN timepoint, 
we performed ELISPOT assays with peptide pools covering 
the MM-associated antigen MAGE-C1/CT7. Afterwards, 
individual peptides belonging to the peptide pools that 
were recognized in this first ELISPOT assay were tested in 
a second ELISPOT assay  (data not shown). Remarkably, in 
two patients we detected reactivity against the same peptide 
(SQSSPVSSFPSSTSS). To our knowledge, this MAGE-C1 
peptide was not previously described to be immunogenic. 
We performed a CD137 staining after stimulation with this 
peptide and observed that it was recognized by CD4+ T 
cells (Figure 5A). We compared the CD4+ T-cell responses 
specific for this MAGE-C1 peptide at both the pre LEN 
and the LEN timepoint in both patients (Figure 5B). In 
patient #02, the peptide was recognized at both timepoints, 
but the number of IFN-γ spots was higher at the pre LEN 
timepoint. In contrast to patient #02, patient #10 showed a 
very low pre LEN response to the peptide (53 spots/million 
cells) and we were not able to detect this response using 
PBMCs from the LEN timepoint. We did not find effects 
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Figure 3: Effects of lenalidomide maintenance therapy on T-cell expression of co-stimulatory and co-inhibitory 
molecules. PBMCs obtained before (pre LEN) and during (LEN) lenalidomide maintenance treatment were examined by flow cytometry 
to determine the expression of co-stimulatory and -inhibitory immune checkpoints  (n = 11). The expression of co-stimulatory and -inhibitory 
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of the lenalidomide treatment on the MAGE-C1 specific 
ELISPOT activity.
DISCUSSION
The positive effect of lenalidomide maintenance 
on PFS and survival after ASCT is generally ascribed to 
immune modulation of the myeloma microenvironment. A 
more profound understanding of the lenalidomide-induced 
changes in the immune environment in MM patients may 
provide new clues for immunotherapeutic interventions 
such as anti-tumor vaccination or checkpoint inhibition. 
We therefore performed a detailed analysis of the immune 
modulatory effects of lenalidomide maintenance therapy 
after ASCT in a homogeneously treated cohort of newly 
diagnosed MM patients. We only studied patients achieving 
a low tumor burden to minimalize immune effects of 
residual tumor cells. Also, such patients are likely to be 
most eligible for immunotherapeutic intervention as they 
benefit from a prolonged PFS. 
Our major finding is that during lenalidomide 
maintenance a marked increase in the number of Tregs with 
mainly suppressive phenotype was observed. The existing 
data on Treg numbers in monoclonal gammopathies are 
not consistent. In patients with monoclonal gammopathy 
of unknown significance (MGUS) or MM, increased 
numbers of Tregs in the peripheral blood were found, 
associated with MM progression [17–22].  In contrast, 
two studies actually showed reduced numbers of 
Tregs in MGUS and MM patients [23, 24]. In more 
advanced myeloma, lenalidomide has been shown to 
increase the number of circulating Treg [14, 25–28]. 
We and others previously showed that Tregs from 
MM patients are endowed with a potent immune 
suppressive capacity [5, 17, 19, 24, 29]. Some studies 
however have shown that these Treg have diminished 
immunosuppressive functional capacity [23, 30]. 
Conflicting results regarding Treg numbers and 
suppressive capacity are most likely in part explained by 
different flow cytometry gating strategies and patient’s 
heterogeneity regarding disease stage or treatment. To 
assess Treg functionality in this study we evaluated the 
Treg phenotype and found that the expression of HLA-
DR, CCR7 and CD62L was increased while CD45RA 
was reduced during lenalidomide maintenance. HLA-DR+ 
Tregs are characterized by contact-dependent immune 
suppression and a high Foxp3 expression [31]. CCR7 
expression on naive Tregs enables them to enter the lymph 
node to control the priming phase of an immune response 
while CCR7 expression on effector/memory like Tregs 
supports emigration from the inflamed site, resulting in 
a more efficient immune suppression [32]. CD62L+ Tregs 
have a high suppressive and proliferative potential [33]. 
CD45RA– Tregs are so-called activated Tregs, endowed 
with a strong suppressive function and a high proliferative 
capacity [19]. Taken together, our data clearly demonstrate 
that lenalidomide maintenance actually enhances the 
suppressive function of the Treg compartment.
Regarding the effector T-cell compartment, we 
observed increased naive CD8+ T cells and memory 
CD4+ and CD8+ T cells whereas terminal effector T 
cells decreased. These terminal effector T cells are 
characterized by a reduced proliferative potential and a 
decreased multipotency [16]. Furthermore, we found that 
the CD8+ T cells obtained after lenalidomide treatment 
produced higher amounts of the pro-inflammatory 
cytokines IFN-γ and TNF-α and of the chemokine MIP-
1β upon polyclonal stimulation. The CD4+/CD8+ T cell 
ratio, known to decrease at MM progression [34, 35], was 
increased. These findings support previous observations 
showing the immune-activating effects of lenalidomide in 
MM patients [11]. 
Since memory T-cells may play an important role 
within the context of prolonged lenalidomide maintenance 
treatment we also examined percentages and functionality 
of these cells. When we stimulated whole PBMC, we did 
not find an effect of the lenalidomide treatment on the 
number of CEF-specific CD8+ T cells. However, when we 
performed a FLUOROSPOT assay using purified CD8+ 
T cells, we found significantly increased percentages of 
antigen-specific CD8+ T cells with a more polyfunctional 
profile. Polyfunctional T cells may have more anti-
myeloma potential. Given the significantly increased 
percentages of Tregs with a more suppressive phenotype 
upon during lenalidomide maintenance treatment, we 
hypothesize that the Tregs present in the PBMC samples 
might have hindered the CD8+ T-cell costimulatory 
effects of lenalidomide in the first assay.  Some studies 
have investigated antigen specific T-cell responses 
upon treatment with a combination of lenalidomide and 
vaccination. Noonan et al. investigated vaccination with 
pneumococcal 7-valent conjugate vaccine (PCV). MM 
patients who received the PCV vaccine while being 
treated with lenalidomide showed increased numbers of 
MM-specific IFN-γ producing T cells in the bone marrow 
[36]. In addition, Krämer et al.  showed an increased 
frequency of T cells specific for the MM antigen HM1.24 
in patients receiving lenalidomide maintenance treatment 
[14].  MAGE-C1, a well-studied tumor associated 
antigen, is expressed on myeloma cells and may be a 
potential target for immunotherapy [37]. However, we 
did not observe an effect of lenalidomide maintenance on 
the frequency of MAGE-C1 specific CD4+ T cells in our 
patients. 
immune checkpoints on CD8+ T cells of one patient are shown as example in panels (A and B), respectively. Numbers shown on the flow 
cytometry plots represent percentages of CD8+ T cells positive for the indicated immune checkpoint molecule. Overview graphs showing 
co-stimulatory and inhibitory -immune checkpoint expression on CD4+ and CD8+ T cells are shown in panel (C). The Wilcoxon matched-
pairs signed rank test was performed to evaluate statistical significant differences, ns: not significant, *p ≤ 0.05, **p ≤ 0.01 and *** p < 0.001.
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Figure 4: Lenalidomide maintenance therapy results in an improved CD8+ T cell functionality, which is hampered by 
non-CD8+ T cells present in the periphery. (A) PBMCs obtained at the pre LEN and the LEN timepoint were examined by IFN-γ 
ELISPOT to measure the CD8+ T-cell response to viral recall epitopes derived for CMV, EBV and influenza (CEF) (n = 6).  The number 
of spot forming units (SFU) as well as the activity in each well was determined. Bar graphs show the mean number of spots per million 
PBMCs or the mean activity of four replicate wells and the error bars show the standard deviation. Spot numbers and activity measured 
upon culture in the absence of peptide were subtracted. (B–E) CD8+ T cells purified from PBMC samples obtained at the pre LEN and 
LEN timepoint were examined by IFN-γ/IL-2/TNF-α FLUOROSPOT to characterize the CD8+ T-cell response to the CEF peptide pool. 
(B–C) Bar graphs show the mean number of spots per million CD8+ T cells of five replicate wells and the error bars show the standard 
deviation. Spot numbers and activity measured upon culture in the absence of peptide were subtracted. (D) Raw data showing three-color 
FLUOROSPOT results. One representative well is shown for each patient and timepoint. Cytokine-specific spots are shown in green 
(IFN-γ), red (TNF-α), blue (IL-2) or overlays of these colors. (E) The pie charts indicate the portion of mono- and polyfunctional CEF-
specific CD8+ T cells. A two-way ANOVA with Sidak’s multiple comparisons test was performed to detect differences between the pre LEN 
and the LEN timepoint, ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
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The expression of inhibitory immune checkpoint 
molecules in the MM microenvironment is of particular 
interest in view of the exciting results currently observed 
with the use of checkpoint inhibitors in various neoplastic 
diseases. High percentages of PD-1+ CD4+ and CD8+ T 
cells are observed in MM patients [6, 38], but following 
ASCT, T-cell expression of PD-1 returns to levels seen in 
healthy individuals [38]. Also bone marrow cytotoxic T 
cells from MM patients express only low levels of PD-1 
[39]. These finding may explain why phase I clinical 
studies have failed to show significant clinical responses 
of PD-1 blockade in MM [39].
Our analysis of immune checkpoint molecules 
during lenalidomide maintenance therapy most strikingly 
showed that T cells form MM patients post ASCT express 
high levels of TIGIT, which was significantly higher than 
its expression on T cells from healthy individuals (data 
not shown). TIGIT is a recently identified inhibitory 
immune checkpoint receptor that is expressed on 
activated T cells, Tregs and NK cells. Interestingly, high 
frequencies of TIGIT+ CD8+ T cells are also detected in 
patients with acute myeloid leukemia (AML) and are 
associated with poor clinical outcome. In AML patients, 
TIGIT+ CD8+ T cells exhibit features of exhaustion [40]. 
Lenalidomide maintenance decreased the number of 
TIGIT+ CD8+ T cells significantly, yet increased TIM-
3+ and LAG-3+ CD4+ T cells and TIM-3+ CD8+ T cells 
were observed. However, the overall expression of TIM-
3 and LAG-3 was relatively low. We also observed an 
increased expression of the immune stimulatory antigens 
CD137, ICOS and CD28 within both the CD4+ and the 
CD8+ T-cell populations, with no effect on the OX40 
expression. 
We previously showed the suppressive capacity 
of the CD11b+ CD14+ HLA-DRlow monocytic MDSC 
population in vitro [5]. We found a modest, but significant, 
reduction in the percentages of CD14+ HLA-DRlow 
PBMCs and CD11b+ CD33+ cells during lenalidomide 
maintenance treatment. In contrast, a previous study 
showed that patients treated with lenalidomide have 
high numbers of CD14+ CD15+ myeloid cells able to 
inhibit T-cell proliferation in vitro [11] At this moment, 
there is no consensus on the frequency and function of 
moMDSCs in MM patients. Görgün et al. found that 
CD11b+ CD14+ HLA-DR–/low MDSCs demonstrated to be 
either absent or less immune suppressive compared to the 
CD11b+ CD14– HLA-DR–/low CD33+ CD15+ MDSCs in 
the MM micro-environment [41]. Brimnes et al. showed 
increased numbers of CD14+ HLA-DR–/low MDSCs in MM 
patients at diagnosis [29]. However, Ramachandran et al. 
demonstrated that although there is no difference in the 
number of CD11b+ CD14+ HLA-DR–/low cells between MM 
patients and healthy individuals, these moMDSCs isolated 
from the BM exert a suppressive function in MM patients 
but not in healthy individuals [42]. Recently, Wang et 
al. showed that increased frequencies of moMDSCs are 
associated with MM tumor progression [43]. Granulocytic 
(CD15+) MDSCs are depleted from the PBMCs and could 
not be investigated in our study.
After the LEN timepoint, the patients in this 
study underwent vaccination with autologous DCs 
electroporated with the MM-associated antigens 
MAGE-C1 and MAGE-A3 while continuing lenalidomide 
maintenance (EUDRACT 2013-000795-15). Clinical and 
immunological responses to the vaccine are investigated 
thoroughly and will further clarify the impact of 
Figure 5: Lenalidomide maintenance therapy does not enhance MM-specific CD4+ T-cell responses. Analysis of T-cell 
responses specific for the MAGE-C1 peptide SQSSPVSSFPSSTSS. (A) CD137 expression on CD4+ and CD8+ T cells from patient#02 at 
the pre LEN timepoint upon in vitro restimulation with the MAGE-C1 peptide. (B) PBMCs obtained at the pre LEN and the LEN timepoint 
were examined by IFN-γ ELISPOT to measure the T-cell response to the MAGE-C1 peptide. The bar graphs show the mean number of 
spots per million cells of four replicate wells and the error bars represent the standard deviation. A two-way ANOVA with Sidak’s multiple 
comparisons test was performed to evaluate statistical significant differences, ns: not significant, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001.
Oncotarget20486www.oncotarget.com
lenalidomide maintenance treatment on the efficacy of the 
vaccination.
In summary, our data show that lenalidomide 
maintenance in vivo induces 1) increased percentages and 
suppressive phenotype of Tregs 2) T cell activation and 
CD8+ T cell antigen specific responses 3) more expression 
of T-cell co-stimulatory but also increased expression of 
some T-cell co-inhibitory molecules, except for TIGIT 4) 
diminished activity of moMDSCs. In view of the positive 
effects of lenalidomide maintenance on PFS and survival 
in myeloma patients after ASCT the balance of these 
effects must be in favor of immune-stimulation against 
residual myeloma cells. However it is likely that additional 
immune interventions such as anti-tumor vaccinations 
could be hampered, especially by Treg expansion. 
Interventions aimed at reducing Tregs during lenalidomide 
maintenance such as the use of cyclophosphamide or 
antibodies such as anti-CD38 may be needed in an attempt 
to make these interventions successful.
MATERIALS AND METHODS
Study subjects
Newly diagnosed, transplant eligible MM patients 
(aged ≤ 65) years were recruited from 3 Belgian University 
Hematology departments: Universitair Ziekenhuis Brussel 
(Brussels), Centre Hospitalier Universitaire de Liège 
(Liège) and Institut Jules Bordet (Brussels). Approval 
for this study was obtained from the institutional review 
boards and informed consent was obtained from all 
participating patients prior to their inclusion in this study, 
according to the Declaration of Helsinki. This study 
is registered in the European Clinical Trials Database 
(EUDRACT Study Number: 2013-000795-15). Response 
assessment was done according to the IMWG response 
criteria [44]. Patients were eligible for study participation 
if they obtained a very good partial response (VGPR) or 
better either after single ASCT or 2 additional cycles of 
a bortezomib based consolidation. Response assessment 
was performed at 100 days after ASCT or after the end of 
consolidation. Maintenance therapy consisted of low dose 
lenalidomide (10 mg qd) continuously until progression. 
Cellular material 
Peripheral blood mononuclear cells (PBMCs) were 
isolated from leukapheresis (pre-LEN timepoint) and 
whole blood (LEN timepoint) samples through lymphoprep 
gradient-centrifugation (Axis-Shield) following the 
manufacturer’s instructions before being cryopreserved. 
Flow cytometry
Flow cytometry analyses were performed on an LSR 
Fortessa flow cytometer (BD Biosciences). Automatic 
compensation was performed using CompBeads (BD 
Biosciences). Fluorescence minus one controls were 
performed to define gates of positivity. Following antibodies 
and reagents were used: biotinylated anti-CD11b, anti-CD33 
PE-Cy7, anti-HLA-DR PE-Cy7, anti-CD15 FITC, anti-CD8 
PE, anti-CD4 APC-Hy, anti-CD127 FITC, anti-CD16 FITC, 
anti-CD45 RO PE, andi-CD45 RA FITC, anti-CD95 PD-
CF594, anti-PD-1 APC, anti CD62L APC (BD Biosciences); 
anti-CD14 APC-Cy7, anti-CD3 BV 605, anti-CD3 PE/
Dazzle 594, anti-CD4 PE-Cy7, anti-CD4 PerCPCy5.5, 
anti-CD56 PE-Cy7, andi-CD28 FITC, anti-CD27 APC, 
anti-ICOS APC-Cy7, anti-CD137 PE, anti-CD137 APC, 
Zombie Yellow Fixable Viability Kit (BioLegend); eFluor 
450 labeled streptavidin, anti-CD8 APC-H7, anti-Foxp3 
APC, anti-CCR7 APC, anti-TIM3 eFluor 450, anti-TIGIT 
PE, anti-LAG3 PerCPeFluor710 (eBioscience), anti-CD25 
PE (Myltenyi Biotec) and anti-OX40 APC (R&D Systems). 
Multiplex assay
CD4+ T cells and CD8+ T cells were purified using 
CD4 or CD8 MicroBeads (MACS technology, Miltenyi 
Biotec), respectively and stimulated Human T-activator 
CD3/CD28 dynabeads (Invitrogen) for 24 hours. 
Supernatants were collected and analyzed using theBio-
Plex Pro Human Cytokine 17-plex (Bio-rad). 
Peptides
CEF-Class I Peptide Pool “Plus” was obtained from 
CTL.  MAGE-C1/CT7 peptides with a length of 15 amino 
acids and with 11 amino acids overlap were obtained from 
EMC Microcollections. Peptides were stored in aliquots 
at –20° C.
ELISPOT assays
The human IFN-γ ELISPOT set from Diaclone 
was used, in combination with PVDF ELISPOT plates 
(Millipore), as previously described [45]. ELISPOT Plates 
were evaluated using the AID ELISPOT automated reader 
system (Autoimmun Diagnostika GmbH) with accessory 
software. 
Ex vivo CEF ELISPOT
PBMCs were thawed, rested for 2 hours at 37° C, 
5% CO2 in a humidified incubator. Afterwards, the cells 
were plated in the ELISPOT plates together with following 
stimuli: medium only (as a negative control) or 0.4 µg/ml 
CEF peptide pool. 
Detection of MAGE-C1 specific T cells by ELISPOT 
upon in vitro restimulation
MAGE-A3 and MAGE-C1-specific T cells were 
expanded prior to the IFN-γ ELISPOT as described 
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previously [46]. The following stimuli were used to screen 
for antigen-specific T cells in the ELISPOT: medium only 
(as a negative control), anti-CD3 and anti-CD28 coated 
microbeads (Invitrogen, as a positive control) or the 
peptide used for the in vitro expansion (1 µg/ml).
FLUOROSPOT assays
CD8+ T cells were purified using CD8 MicroBeads 
(MACS technology, Miltenyi Biotec) and plated in the 
pre-coated IFN-γ/IL-2/TNF-α FLUOROSPOT plates 
(Mabtech) together with following stimuli: medium only 
(as a negative control) or 0.4 µg/ml CEF peptide pool. 
The FLUOROSPOT plates were developed according to 
the manufacturers’ instructions and evaluated using the 
ImmunoSpot S6 Ultra-V (CTL) with accessory software. 
Data analysis
Flow cytometry data were analyzed using FACS 
DIVA (BD Biosciences) and FlowJo (Tree Star inc.) 
software. Statistical analysis was performed using 
GraphPad Prism software. 
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